View Filing Data

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2017	Apr. 28, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Entity Registrant Name	OPGEN INC
Entity Central Index Key	0001293818
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	OPGN
Entity Common Stock, Shares Outstanding		27,394,290

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 1,670,311	$ 4,117,324
Accounts receivable, net	379,246	542,420
Inventory, net	642,961	692,368
Prepaid expenses and other current assets	267,971	329,646
Total current assets	2,960,489	5,681,758
Property and equipment, net	743,521	800,723
Goodwill	600,814	600,814
Intangible assets, net	1,554,044	1,620,998
Other noncurrent assets	298,081	279,752
Total assets	6,156,949	8,984,045
Current liabilities
Accounts payable	2,017,202	2,232,563
Accrued compensation and benefits	1,019,962	578,480
Accrued liabilities	883,105	1,215,283
Deferred revenue	31,233	37,397
Short-term notes payable	998,958	1,023,815
Current maturities of long-term capital lease obligation	170,297	184,399
Total current liabilities	5,120,757	5,271,937
Deferred rent	374,194	398,084
Long-term capital lease obligation and other noncurrent liabilities	107,940	146,543
Total liabilities	5,602,891	5,816,564
Commitments (Note 8)
Stockholders' equity
Common stock, $0.01 par value; 200,000,000 shares authorized; 27,377,490 and 25,304,270 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively	273,775	253,042
Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued and outstanding at March 31, 2017 and December 31, 2016, respectively	0	0
Additional paid-in capital	138,546,915	136,199,382
Accumulated other comprehensive income	2,419	6,176
Accumulated deficit	(138,269,051)	(133,291,119)
Total stockholders’ equity	554,058	3,167,481
Total liabilities and stockholders’ equity	$ 6,156,949	$ 8,984,045

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	27,377,490	25,304,270
Common stock, shares outstanding	27,377,490	25,304,270
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue
Product sales	$ 734,502	$ 947,219
Laboratory services	16,105	129,420
Collaboration revenue	21,164	0
Total revenue	771,771	1,076,639
Operating expenses
Cost of products sold	424,950	345,967
Cost of services	100,233	315,709
Research and development	2,122,515	1,953,429
General and administrative	1,969,216	1,538,046
Sales and marketing	1,105,586	1,399,435
Total operating expenses	5,722,500	5,552,586
Operating loss	(4,950,729)	(4,475,947)
Other expense
Interest and other income	21	173
Interest expense	(29,844)	(41,734)
Foreign currency transaction gains	2,620	11,328
Total other expense	(27,203)	(30,233)
Loss before income taxes	(4,977,932)	(4,506,180)
Provision for income taxes	0	0
Net loss	(4,977,932)	(4,506,180)
Preferred stock dividends and beneficial conversion	0	0
Net loss available to common stockholders	$ (4,977,932)	$ (4,506,180)
Net loss per common share - basic and diluted	$ (0.19)	$ (0.36)
Weighted average shares outstanding - basic and diluted	26,079,461	12,568,941
Net loss	$ (4,977,932)	$ (4,506,180)
Other comprehensive loss - foreign currency translation	(3,757)	(1,112)
Comprehensive loss	$ (4,981,689)	$ (4,507,292)

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities
Net loss	$ (4,977,932)	$ (4,506,180)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	159,863	168,440
Loss on disposal of property and equipment	0	6,068
Noncash interest expense	2,087	1,042
Share-based compensation	245,405	261,497
Changes in operating assets and liabilities:
Accounts receivable	163,174	39,411
Inventory	49,407	(97,849)
Other assets	43,346	199,182
Accounts payable	(215,361)	(80,276)
Accrued compensation and other liabilities	75,683	211,979
Deferred revenue	(6,164)	869
Net cash used in operating activities	(4,460,492)	(3,795,817)
Cash flows from investing activities
Purchases of property and equipment (net of proceeds on disposals)	(27,022)	(1,644)
Net cash used in investing activities	(27,022)	(1,644)
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs	2,122,861	0
Proceeds from exercise of stock options and warrants	0	9,271
Payments on debt	(25,898)	0
Payments on capital lease obligations	(52,706)	(63,327)
Net cash provided by/(used in) financing activities	2,044,257	(54,056)
Effects of exchange rates on cash	(3,756)	5,254
Net decrease in cash and cash equivalents	(2,447,013)	(3,846,263)
Cash and cash equivalents at beginning of period	4,117,324	7,814,220
Cash and cash equivalents at end of period	1,670,311	3,967,957
Supplemental disclosure of cash flow information
Cash paid for interest	10,702	13,021
Supplemental disclosures of noncash investing and financing activities:
Property and equipment purchased on credit	8,685	27,767
Deferred and accrued financing costs	$ 0	$ 52,210

Organization

3 Months Ended

Mar. 31, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Organization

Note 1 – Organization

OpGen, Inc. (“OpGen” or the “Company”) was incorporated in Delaware in 2001. References in this report to the “Company” include OpGen and its wholly-owned subsidiaries. The Company’s headquarters are in Gaithersburg, Maryland, and its principal operations are in Gaithersburg, Maryland and Woburn, Massachusetts. The Company also has operations in Copenhagen, Denmark. The Company operates in one business segment.

OpGen is a precision medicine company using molecular diagnostics and bioinformatics to help combat infectious disease. The Company is developing molecular information products and services to combat infectious disease in global healthcare settings, helping to guide clinicians with more rapid information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms (“MDROs”). Its proprietary DNA tests and bioinformatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize patient care decisions and protect the hospital biome through customized screening and surveillance products and services.

The Company’s molecular diagnostics and bioinformatics offerings combine its Acuitas DNA tests, Acuitas Lighthouse bioinformatics services, and CLIA lab services for MDRO surveillance. The Company is working to deliver its products and services, some in development, to a global network of customers and partners. These include:

•

Its Acuitas DNA tests, which provide rapid microbial identification, and antibiotic resistance gene information. These products include (i) the QuickFISH family of FDA-cleared and CE-marked diagnostics used to rapidly detect pathogens in positive blood cultures, (ii) the Acuitas MDRO Gene Test to detect, type, track, and trend antibiotic resistant organisms in real-time and (iii) the Acuitas Rapid Test in development. The Company is working to provide actionable, precise diagnostic information powered by pathogen surveillance data collected through hospital screening programs and a network of hospital and public health laboratories globally.

•

Its Acuitas Lighthouse bioinformatics systems, which are cloud-based HIPAA compliant bioinformatics offerings that combine clinical lab test results with patient and hospital information and provide analytics to help manage MDROs in the hospital and patient care environment. These include its Acuitas Lighthouse informatics, which can be specific to a healthcare facility, public health department or collaborator, such as a pharmaceutical company, and its Acuitas Lighthouse Knowledgebase, a proprietary data warehouse in development to include genomic data matched with antibiotic susceptibility information for microbes and patient information from healthcare providers, in which the Company is beginning to collect and store MDRO information from a variety of sources for use with its Acuitas Rapid Test in development.

The Company’s operations are subject to certain risks and uncertainties. The risks include rapid technology changes, the need to manage growth, the need to retain key personnel, the need to protect intellectual property and the need to raise additional capital financing on terms acceptable to the Company. The Company’s success depends, in part, on its ability to develop and commercialize its proprietary technology as well as raise additional capital.

Liquidity and management's plans	3 Months Ended
Liquidity and management's plans	Mar. 31, 2017
Liquidation Basis Of Accounting Abstract [Abstract]
Liquidity and management's plans	Note 2 – Liquidity and management’s plans The accompanying unaudited condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since inception, the Company has incurred, and continues to incur, significant losses from operations. The Company has funded its operations primarily through external investor financing arrangements and has raised funds in 2017 and 2016, including: In September 2016, the Company entered into a Sales Agreement (the "Sales Agreement") with Cowen and Company LLC ("Cowen") pursuant to which the Company may offer and sell from time to time, up to an aggregate of $25 million of shares of its common stock through Cowen, as sales agent, with initial sales limited to an aggregate of $11.5 million. Pursuant to the Sales Agreement, Cowen may sell the shares of the Company’s common stock by any method permitted by law deemed to be an "at the market” offering as defined in Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”), including, without limitation, sales made by means of ordinary brokers' transactions on The NASDAQ Capital Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise directed by the Company. The Company pays Cowen compensation equal to 3.0% of the gross proceeds from the sales of common stock pursuant to the terms of the Sales Agreement. As of March 31, 2017, the Company has sold an aggregate of approximately 5.7 million shares of its common stock under this at the market offering resulting in aggregate net proceeds to the Company of approximately $6.5 million, and gross proceeds of $6.9 million. As of March 31, 2017, remaining availability under the at the market offering is $4.6 million. For the three months ended March 31, 2017, the Company has sold approximately 2.1 million shares of its common stock under this at the market offering resulting in aggregate net proceeds to the Company of approximately $2.1 million, and gross proceeds of $2.2 million. In May and June 2016, the Company offered and sold units in a private offering to members of management and employees and to accredited investors, including Merck Global Health Innovation Fund, LLC (“Merck GHI”) and jVen Capital, LLC (“jVen Capital”), each unit consisting of either (i) one share of common stock and a detachable stock purchase warrant to purchase an additional 0.75 shares of common stock, or (ii) one share of non-voting convertible preferred stock and a detachable stock purchase warrant to purchase an additional 0.75 shares of common stock, at a price of $1.14 per unit. The total net proceeds to the Company, after deducting offering commissions and expenses were $9.5 million. The Company used the proceeds for working capital and general corporate purposes. Pursuant to the private placement, the Company issued 6,744,127 shares of common stock, 2,309,428 shares of non-voting convertible preferred stock and stock purchase warrants to acquire an additional 6,790,169 shares of common stock. To meet its capital needs, the Company is considering multiple alternatives, including, but not limited to, additional equity financings, debt financings and other funding transactions, licensing and/or partnering arrangements and business combination transactions. There can be no assurance that the Company will be able to complete any such transaction on acceptable terms or otherwise. The Company believes that current cash on hand will be sufficient to fund operations through a portion of the second quarter of 2017. This has led management to conclude that substantial doubt about the Company’s ability to continue as a going concern exists. In the event the Company is unable to successfully raise additional capital during the second quarter of 2017, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated. Accordingly, in such circumstances the Company would be compelled to immediately reduce general and administrative expenses and delay research and development projects, including the purchase of scientific equipment and supplies, until it is able to obtain sufficient financing. If such sufficient financing is not received timely, the Company would then need to pursue a plan to license or sell its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection. Furthermore, the $1.0 million Merck Note (see Note 4) matures in July 2017. If the Company is unable to repay the note, negotiate its conversion or extend its term, the assets of the Company may be seized, as the note is secured by a lien on all the Company’s assets.

Summary of significant accounting policies

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Summary of significant accounting policies

Note 3 - Summary of significant accounting policies

Basis of presentation and consolidation

The Company has prepared the following unaudited condensed, consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission and the standards of accounting measurement set forth in the Interim Reporting Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted, although the Company believes that the disclosures made are adequate to make the information not misleading. The Company recommends that the following condensed, consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s latest Annual Report on Form 10-K. In the opinion of management, all adjustments that are necessary for a fair presentation of the Company’s financial position for the periods presented have been reflected. All adjustments are of a normal, recurring nature, unless otherwise stated. The interim condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December 31, 2016 consolidated balance sheet included herein was derived from the audited consolidated financial statements, but do not include all disclosures including notes required by GAAP for complete financial statements.

The accompanying unaudited interim condensed consolidated financial statements include the accounts of OpGen and its wholly-owned subsidiaries; all intercompany transactions and balances have been eliminated. The Company operates in one business segment.

Foreign currency

One of the Company’s subsidiaries is located in Copenhagen, Denmark and uses the Danish Krone as its functional currency. As a result, all assets and liabilities are translated into U.S. dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the average exchange rates prevailing during the reporting period. Translation adjustments are reported in accumulated other comprehensive income, a component of stockholders’ equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at March 31, 2017 and December 31, 2016.

Foreign currency transaction gains and losses, excluding gains and losses on intercompany balances where there is no current intent to settle such amounts in the foreseeable future, are included in the determination of net loss. Unless otherwise noted, all references to “$” or “dollar” refer to the U.S. dollar.

Use of estimates

In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying condensed consolidated financial statements, estimates are used for, but not limited to, share-based compensation, allowances for doubtful accounts and inventory obsolescence, valuation of derivative financial instruments, beneficial conversion features of convertible debt, deferred tax assets and liabilities and related valuation allowance, depreciation and amortization and estimated useful lives of long-lived assets. Actual results could differ from those estimates.

Fair value of financial instruments

All financial instruments classified as current assets and liabilities are carried at cost, which approximates fair value, because of the short-term maturities of those instruments.

Cash and cash equivalents

The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the federal government agency (“FDIC”) insured limits of $250,000. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.

At March 31, 2017 and December 31, 2016, the Company has funds totaling $243,380, which are required as collateral for letters of credit benefiting its landlords and for credit card processors. These funds are reflected in other noncurrent assets on the accompanying condensed consolidated balance sheets.

Accounts receivable

The Company’s accounts receivable result from revenues earned but not collected from customers. Credit is extended based on an evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are due within 30 to 60 days and are stated at amounts due from customers. The Company evaluates if an allowance is necessary by considering a number of factors, including the length of time accounts receivable are past due, the Company’s previous loss history and the customer’s current ability to pay its obligation. If amounts become uncollectible, they are charged to operations when that determination is made. The allowance for doubtful accounts was $31,118 and $26,716 as of March 31, 2017 and December 31, 2016, respectively.

No individual customer represented in excess of 10% of revenues for the three months ended March 31, 2017 and 2016. At March 31, 2017, no individual customer represented in excess of 10% of total accounts receivable.

Inventory

Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:

	March 31, 2017		December 31, 2016
Raw materials and supplies	$	410,945	$	479,479
Work-in process		68,031		27,422
Finished goods		163,985		185,467
Total	$	642,961	$	692,368

Inventory now includes reagents and components for QuickFISH and PNA FISH kit products, and reagents and supplies used for the Company’s laboratory services. Inventory reserves for obsolescence and expirations were $134,679 and $704,516 at March 31, 2017 and December 31, 2016, respectively. The primary driver of the decrease in the inventory reserves for obsolescence and expirations is the scrapping of legacy Argus Whole Genome Mapping Systems and the portion of the reagents and supplies used for Argus consumable kits. All items scrapped in the three months ended March 31, 2017 were fully reserved for as of December 31, 2016.

Long-lived assets

Property and equipment

Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. During the three months ended March 31, 2017 and 2016, the Company determined that its property and equipment was not impaired.

Intangible assets and goodwill

Intangible assets and goodwill as of March 31, 2017 consist of finite-lived intangible assets and goodwill.

Finite-lived intangible assets

Finite-lived intangible assets include trademarks, developed technology and customer relationships and consisted of the following as of March 31, 2017 and December 31, 2016:

			March 31, 2017					December 31, 2016
	Cost		Accumulated Amortization			Net Balance		Accumulated Amortization			Net Balance
Trademarks and tradenames	$	461,000	$	(79,101	)	$	381,899	$	(67,575	)	$	393,425
Developed technology		458,000		(112,254	)		345,746		(95,898	)		362,102
Customer relationships		1,094,000		(267,601	)		826,399		(228,529	)		865,471
	$	2,013,000	$	(458,956	)	$	1,554,044	$	(392,002	)	$	1,620,998

Finite-lived intangible assets are amortized over their estimated useful lives. The estimated useful life of trademarks was 10 years, developed technology was 7 years, and customer relationships was 7 years. The Company reviews the useful lives of intangible assets when events or changes in circumstances occur which may potentially impact the estimated useful life of the intangible assets.

Total amortization expense of intangible assets was $66,954 for each of the three months ended March 31, 2017 and 2016, respectively. The Company estimates amortization expense related to intangible assets will be $268,000 per year for each of the next five years.

Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, the Company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. During the three months ended March 31, 2017 and 2016, the Company determined that its finite-lived intangible assets were not impaired.

In accordance with ASC 360-10, the Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that long-lived assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets. During the fourth quarter of 2016, events and circumstances indicated the Company’s intangible assets might be impaired. However, management’s estimate of undiscounted cash flows indicated that such carrying amounts were expected to be recovered. Nonetheless, it is reasonably possible that the estimate of undiscounted cash flows may change in the near term resulting in the need to write down those assets to fair value. Management’s estimate of cash flows might change if the development of the Company’s automated rapid pathogen identification product technological advances does not progress as planned, the timeline of development is delayed, there are changes to the estimates of the future marketability of this product or if the Company cannot obtain sufficient funding to pay for its development.

Goodwill

Goodwill represents the excess of the purchase price paid in a July 2015 merger transaction in which the Company acquired AdvanDx, Inc. and its subsidiary (the “Merger”) over the fair values of the acquired tangible or intangible assets and assumed liabilities. Goodwill is not tax deductible in any relevant jurisdictions. The Company’s goodwill balance as of March 31, 2017 and December 31, 2016 was $600,814.

The Company conducts an impairment test of goodwill on an annual basis as of October 1 of each year, and will also conduct tests if events occur or circumstances change that would, more likely than not, reduce the Company’s fair value below its net equity value.

Revenue recognition

The Company recognizes revenue primarily from sales of its products and services when the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the selling price is fixed or determinable; and collectability is reasonably assured. At times, the Company sells products and services, or performs software development, under multiple-element arrangements with separate units of accounting; in these situations, total consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics.

Amounts billed to customers for shipping and handling are included in revenue when the related product or service revenue is recognized. Shipping and handling costs are included in cost of products sold.

Revenue from sales of QuickFISH, PNA FISH and XpressFISH diagnostic test products

Revenue is recognized upon shipment to the customer.

Revenue from providing laboratory services

The Company recognizes revenue associated with laboratory services contracts when the service has been performed and reports are made available to the customer.

Revenue from funded software development arrangements

The Company’s funded software development arrangements generally consist of multiple elements. Total arrangement consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics. When funded software development arrangements include substantive research and development milestones, revenue is recognized for each such milestone when the milestone is achieved and is due and collectible. Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with achievement of the milestone.

Revenue from license arrangements

The Company recognizes revenue from licenses of its technologies over the applicable license term.

Revenue from sales of the reagents and supplies used for Argus consumable kits

Revenue is recognized for sales of the reagents and supplies used for Argus consumable kits upon shipment to the customer.

Share-based compensation

Share-based compensation expense is recognized at fair value. The fair value of share-based compensation to employees and directors is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. For all time-vesting awards granted, expense is amortized using the straight-line attribution method. The Company accounts for forfeitures as they occur.

Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.

Income taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred income tax assets to the amount expected to be realized.

Tax benefits are initially recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially, and subsequently, measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts.

The Company had federal net operating loss (“NOL”) carryforwards of $151.0 million at December 31, 2016. Despite the NOL carryforwards, which begin to expire in 2022, the Company may have future tax liability due to alternative minimum tax or state tax requirements. Also, use of the NOL carryforwards may be subject to an annual limitation as provided by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”). To date, the Company has not performed a formal study to determine if any of its remaining NOL and credit attributes might be further limited due to the ownership change rules of Section 382 or Section 383 of the Code. The Company will continue to monitor this matter going forward. There can be no assurance that the NOL carryforwards will ever be fully utilized.

Loss per share

Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period.

For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.

For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of anti-dilutive shares, consisting of (i) common stock options, (ii) stock purchase warrants, and (iii) restricted stock units representing the right to acquire shares of common stock which have been excluded from the computation of diluted loss per share, was 14.0 million shares and 5.9 million shares as of March 31, 2017 and 2016, respectively.

Recent accounting pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing, and uncertainty of revenue arising from contracts with customers. In August 2015, the FASB issued guidance approving a one-year deferral, making the standard effective for reporting periods beginning after December 15, 2017, with early adoption permitted only for reporting periods beginning after December 15, 2016. In March 2016, the FASB issued guidance to clarify the implementation guidance on principal versus agent considerations for reporting revenue gross rather than net, with the same deferred effective date. In April 2016, the FASB issued guidance to clarify the identification of performance obligations and licensing arrangements. In May 2016, the FASB issued guidance addressing the presentation of sales and other similar taxes collected from customers, providing clarification of the collectability criterion assessment, as well as clarifying certain transition requirements. The Company has identified its major revenue streams and it plans on completing formal contract reviews in the second half of 2017. While the Company continues to assess all of the potential impacts of these ASUs, the Company does not expect the implementation of these ASUs to have a significant impact on the Company’s consolidated results of operations, financial position and cash flows. The Company will assess the disclosure requirements prescribed by these ASUs in the second half of 2017 and it may be required to expand its disclosures. The Company will assess the method of adoption in the second half of 2017.

In July 2015, the FASB issued accounting guidance for inventory. Under the guidance, an entity should measure inventory within the scope of this guidance at the lower of cost and net realizable value, except when inventory is measured using LIFO or the retail inventory method. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. In addition, the FASB has amended some of the other inventory guidance to more clearly articulate the requirements for the measurement and disclosure of inventory. The standard is effective for reporting periods beginning after December 15, 2016. The amendments in this pronouncement should be applied prospectively, with earlier application permitted. The Company adopted this guidance effective January 1, 2017, on a prospective basis. The adoption of this new guidance did not have a material impact on the Company’s consolidated financial statements.

In February 2016, the FASB issued guidance for the accounting for leases. The guidance requires lessees to recognize assets and liabilities related to long-term leases on the consolidated balance sheets and expands disclosure requirements regarding leasing arrangements. The guidance is effective for reporting periods beginning after December 15, 2018 and early adoption is permitted. The guidance must be adopted on a modified retrospective basis and provides for certain practical expedients. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its consolidated financial statements.

The Company has evaluated all other issued and unadopted Accounting Standards Updates and believes the adoption of these standards will not have a material impact on its results of operations, financial position, or cash flows.

2015 Merck GHI financing	3 Months Ended
2015 Merck GHI financing	Mar. 31, 2017
Common Stock And Note Purchase Agreement [Abstract]
2015 Merck GHI financing	Note 4 – 2015 Merck GHI financing In July 2015, in connection with the Merger, the Company entered into a Purchase Agreement with Merck GHI, pursuant to which Merck GHI purchased 1,136,364 shares of common stock of the Company at $4.40 per share for gross proceeds of $5.0 million. Pursuant to the Purchase Agreement, the Company also issued to Merck GHI a 8% Senior Secured Promissory Note (the “Merck Note”) in the principal amount of $1.0 million with a two-year maturity date from the date of issuance. The Company’s obligations under the Merck Note are secured by a lien on all of the Company’s assets. Under the Purchase Agreement, Merck GHI has the right to participate in future securities offerings made by the Company. Also in July 2015, the Company entered into a Registration Rights Agreement with Merck GHI and certain stockholders, which will require the Company to register for resale by such holders in the future, such shares of Company common stock that cannot be sold under an exemption from such registration. The Company incurred issuance costs of approximately $50,000 related to the financing. Approximately $8,000 of the issuance costs were deferred as debt issuance costs and netted against notes payable in the accompanying condensed consolidated balance sheets as a result of the Company’s adoption of the new accounting guidance in 2016, and are being amortized as interest expense over the life of the Merck Note. The remaining $42,000 of issuance costs were charged to additional paid-in capital.

Fair value measurements

3 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Fair value measurements

Note 5 - Fair value measurements

The Company classifies its financial instruments using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

•

Level 1 - defined as observable inputs such as quoted prices in active markets;

•

Level 2 - defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

•

Level 3 - defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions such as expected revenue growth and discount factors applied to cash flow projections.

For the three months ended March 31, 2017, the Company has not transferred any assets between fair value measurement levels.

Financial assets and liabilities measured at fair value on a recurring basis

The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the hierarchy. The Company has no financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2017.

Financial assets and liabilities carried at fair value on a non-recurring basis

The Company does not have any financial assets and liabilities measured at fair value on a non-recurring basis.

Non-financial assets and liabilities carried at fair value on a recurring basis

The Company does not have any non-financial assets and liabilities measured at fair value on a recurring basis.

Non-financial assets and liabilities carried at fair value on a non-recurring basis

The Company measures its long-lived assets, including property and equipment and intangible assets (including goodwill), at fair value on a non-recurring basis when they are deemed to be impaired. No such fair value impairment was recognized in the three months ended March 31, 2017 and 2016.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Debt	3 Months Ended
Debt	Mar. 31, 2017
Debt Disclosure [Abstract]
Debt	Note 6 - Debt As of March 31, 2017 and December 31, 2016, the Company’s outstanding debt consisted of the $1.0 million Merck Note that is due in July 2017 (see Note 4). Total interest expense on all debt instruments was $29,844 and $41,734 for the three months ended March 31, 2017 and 2016, respectively.

Stockholders' equity

3 Months Ended

Mar. 31, 2017

Stockholders Equity Note [Abstract]

Stockholders' equity

Note 7 - Stockholders’ equity

As of March 31, 2017, the Company has 200,000,000 shares of authorized common shares and 27,377,490 issued and outstanding, and 10,000,000 of authorized preferred shares, of which none were issued or outstanding.

In September 2016, the Company entered into the Sales Agreement with Cowen pursuant to which the Company may offer and sell from time to time, up to an aggregate of $25 million of shares of its common stock through Cowen, as sales agent, with initial sales limited to an aggregate of $11.5 million. Pursuant to the Sales Agreement, Cowen may sell the shares of common stock by any method permitted by law deemed to be an "at the market” offering as defined in Rule 415 of the Securities Act, including, without limitation, sales made by means of ordinary brokers' transactions on The NASDAQ Capital Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise directed by the Company. The Company pays Cowen compensation equal to 3.0% of the gross proceeds from the sales of common stock pursuant to the terms of the Sales Agreement. As of March 31, 2017, the Company has sold an aggregate of approximately 5.7 million shares of its common stock under this at the market offering resulting in aggregate net proceeds to the Company of approximately $6.5 million, and gross proceeds of $6.9 million. As of March 31, 2017, remaining availability under the at the market offering is $4.6 million. For the three months ended March 31, 2017, the Company has sold approximately 2.1 million shares of its common stock under this at the market offering resulting in aggregate net proceeds to the Company of approximately $2.1 million, and gross proceeds of $2.2 million.

In May and June 2016, the Company offered and sold units in a private offering to members of management and employees and to accredited investors, including Merck GHI and jVen Capital, each unit consisting of either (i) one share of common stock and a detachable stock purchase warrant to purchase an additional 0.75 shares of common stock, or (ii) one share of non-voting convertible preferred stock and a detachable stock purchase warrant to purchase an additional 0.75 shares of common stock, at a price of $1.14 per unit. The total net proceeds to the Company, after deducting offering commissions and expenses was $9.5 million. Pursuant to the private placement the Company issued 6,744,127 shares of common stock, 2,309,428 of Series A non-voting convertible preferred stock and stock purchase warrants to acquire an additional 6,790,169 shares of common stock. Under the purchase agreement, the Company granted registration rights to the investors in the private financing.

Each share of Series A non-voting convertible preferred stock was convertible at the option of the holder in whole or in part and from time to time into one share of common stock, was entitled to dividends on an “as converted basis” when and if dividends are issued to common stockholders, and would have participated in liquidation on a pari passu basis with common stockholders. The preferred stock was classified as permanent equity. The stock purchase warrants issued as part of the units are exercisable at $1.3125 per share beginning 90 days after closing for five years, expiring on May 18, 2021. The warrants are classified as permanent equity at March 31, 2017. In connection with the issuance of Series A non-voting convertible preferred stock, the Company recognized a beneficial conversion feature of $332,550 as a deemed dividend to the preferred shareholders. Holders of the Series A non-voting convertible preferred stock subsequently converted all 2,309,428 shares of preferred stock into 2,309,428 shares of common stock.

The Company filed a registration statement on Form S-3 on June 13, 2016 to register for resale by the investors, from time to time, of the shares of common stock acquired, or underlying the warrants issued, in the private offering. On July 20, 2016, the registration statement was declared effective by the SEC.

Stock options

In 2008, the Company adopted the 2008 Stock Option and Restricted Stock Plan (the “2008 Plan”), pursuant to which the Company’s Board of Directors could grant either incentive or non-qualified stock options or shares of restricted stock to directors, key employees, consultants and advisors.

In April 2015, the Company adopted, and the Company’s stockholders approved, the 2015 Equity Incentive Plan (the “2015 Plan”); the 2015 Plan became effective upon the execution and delivery of the underwriting agreement for the Company’s initial public offering in May 2015. Following the effectiveness of the 2015 Plan, no further grants will be made under the 2008 Plan. The 2015 Plan provides for the granting of incentive stock options within the meaning of Section 422 of the Code to employees and the granting of non-qualified stock options to employees, non-employee directors and consultants. The 2015 Plan also provides for the grants of restricted stock, restricted stock units, stock appreciation rights, dividend equivalents and stock payments to employees, non-employee directors and consultants.

Under the 2015 Plan, the aggregate number of shares of the common stock authorized for issuance may not exceed (1) 1,355,000 plus (2) the sum of the number of shares subject to outstanding awards under the 2008 Plan as of the 2015 Plan’s effective date, that are subsequently forfeited or terminated for any reason before being exercised or settled, plus (3) the number of shares subject to vesting restrictions under the 2008 Plan as of the 2015 Plan’s effective date that are subsequently forfeited. In addition, the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Company’s Board of Directors. Shares subject to awards granted under the 2015 Plan that are forfeited or terminated before being exercised or settled, or are not delivered to the participant because such award is settled in cash, will again become available for issuance under the 2015 Plan. However, shares that have actually been issued shall not again become available unless forfeited. As of March 31, 2017, 1,145,402 shares remain available for issuance under the 2015 Plan, which includes 1,012,171 shares automatically added to the 2015 Plan on January 1, 2017.

On April 28, 2016, the Board of Directors of the Company made a stock option award to Evan Jones, the Company’s Chief Executive Officer (“CEO”) and Chairman of the Board. The non-qualified stock option award to acquire 766,500 shares of common stock represented approximately 6% of outstanding shares of common stock as of the date of the award. The stock option grant has an exercise price of $1.35 per share, a ten-year term and a vesting schedule of 25% vesting of the award on the first annual anniversary of the date of grant and then 6.25% vesting each quarter thereafter over three additional years. The plan under which the award was made incorporates by reference the provisions of the Company’s 2015 Plan applicable to stock option awards. The stock option award was contingent on receipt of stockholder approval, as the award was made outside of the Company’s stockholder-approved incentive plans. The stockholders approved the stock option award at the Company’s Annual Meeting of Stockholders held on June 22, 2016.

For the three months ended March 31, 2017 and 2016, the Company recognized stock compensation expense as follows:

	Three Months Ended March 31,
	2017		2016
Cost of services	$	1,823	$	4,312
Research and development		57,778		62,218
General and administrative		152,476		172,103
Sales and marketing		33,328		22,864
	$	245,405	$	261,497

No income tax benefit for stock-based compensation arrangements was recognized in the condensed consolidated statements of operations and comprehensive loss due to the Company’s net loss position.

During the three months ended March 31, 2017, the Company granted stock options to acquire 723,600 shares of common stock at a weighted average exercise price of $1.03 per share and a weighted average grant date fair value of $0.54 per share. 4,863 options were forfeited during the three months ended March 31, 2017 at a weighted average exercise price of $1.82 per share. The Company had total stock options to acquire 3,514,071 shares of common stock outstanding at March 31, 2017.

Restricted stock units

In the fourth quarter of 2015, the Company granted restricted stock units to acquire 75,000 shares of common stock, with a weighted average grant date fair value of $1.70 per share, 18,750 shares of which remain outstanding as of March 31, 2017. No restricted stock units vested and no restricted stock units were forfeited during the three months ended March 31, 2017.

Stock purchase warrants

At March 31, 2017 and December 31, 2016, the following warrants to purchase shares of common stock were outstanding:

				Outstanding at
Issuance	Exercise Price		Expiration	March 31, 2017		December 31, 2016
August 2007	$	7.91	August 2017		8,921		8,921
March 2008	$	790.54	March 2018		46		46
November 2009	$	7.91	November 2019		6,674		6,674
January 2010	$	7.91	January 2020		6,674		6,674
March 2010	$	7.91	March 2020		1,277		1,277
November 2011	$	7.91	November 2021		5,213		5,213
December 2011	$	7.91	December 2021		664		664
March 2012	$	109.90	March 2019		4,125		4,125
February 2015	$	6.60	February 2025		225,011		225,011
May 2015	$	6.60	May 2020		3,457,750		3,457,750
May 2016	$	1.31	May 2021		4,739,348		4,739,348
June 2016	$	1.31	May 2021		2,050,821		2,050,821
					10,506,524		10,506,524

The warrants listed above were issued in connection with various debt, equity or development contract agreements.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Commitments	3 Months Ended
Commitments	Mar. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments	Note 8 - Commitments Operating leases The Company leases a facility in Woburn, Massachusetts under an operating lease that expires January 30, 2022. The Company also leases a facility in Gaithersburg, Maryland under an operating lease that expires January 31, 2021, with one additional five-year renewal at the Company’s election. Additionally, the Company leases office space in Denmark; this lease is currently on a month-to-month basis. Rent expense under the Company’s facility operating leases for the three months ended March 31, 2017 and 2016 was $232,836 and $254,044, respectively. Capital leases The Company leases computer equipment, office furniture, and equipment under various capital leases. The leases expire at various dates through 2021. The leases require monthly principal and interest payments. Registration and other stockholder rights In connection with the various investment transactions, the Company entered into registration rights agreements with stockholders, pursuant to which the investors were granted certain demand registration rights and/or piggyback and/or resale registration rights in connection with subsequent registered offerings of the Company’s common stock.

License agreements, research collaborations and development agreements	3 Months Ended
	Mar. 31, 2017
License Agreements Research Collaborations And Development Agreements [Abstract]
License Agreements, Research Collaborations and Development Agreements	Note 9 - License agreements, research collaborations and development agreements The Company is a party to five license agreements to acquire certain patent rights and technologies; two related to the FISH product line and three related to the Argus and MapIt product lines. Royalties are incurred upon the sale of a product or service which utilizes the licensed technology. Certain of the agreements require the Company to pay minimum royalties or license maintenance fees. The Company recognized net royalty expense of $69,245 and $69,854 for the three months ended March 31, 2017 and 2016, respectively. Annual future minimum royalty fees are $250,000 under these agreements. In June 2016, the Company entered into a license agreement with Hitachi High-Technologies Corporation (“Hitachi”), pursuant to which it resolved various matters with respect to previously delivered milestones under the technology development agreement and provided a development license and commercial products license to certain technology. The license agreement contains non-contingent multiple elements (the licenses) that the Company determined did not have stand alone value, and a contingent substantive milestone. The licenses are treated as a single unit of accounting and the Company will recognize the revenue associated with that unit of accounting over the applicable license period. During the three months ended March 31, 2017, the Company recognized $6,164 of revenue related to the license agreement.

Related party transactions	3 Months Ended
Related party transactions	Mar. 31, 2017
Related Party Transactions [Abstract]
Related party transactions	Note 10 - Related party transactions In March 2014, the Company entered into a supply agreement with Fluidigm Corporation (“Fluidigm”) under which Fluidigm supplies the Company with its microfluidic test platform for use in manufacturing the Acuitas MDRO Gene Test. The Company’s CEO and Chairman of the Board of Directors is a director of Fluidigm. On July 12, 2015, the Company entered into a letter agreement (the “Fluidigm Agreement”) with Fluidigm to expand the companies’ existing relationship to include collaborating on the development of test kits and custom analytic instruments for identification, screening and surveillance testing of MDROs. The Fluidigm Agreement also expands the existing Supply Agreement between the Company and Fluidigm, and provides for expansion of the gene targets and organisms to be tested on the Company’s existing CLIA lab-based tests, the Acuitas MDRO Gene Test and the Acuitas Resistome Test, using Fluidigm technologies and products. Additionally, Fluidigm has agreed not to develop or directly collaborate with any third party to develop an FDA approved or CE-marked diagnostic test for the purpose of detecting resistance genes for identified MDROs if the Company meets certain minimum purchase commitments and other requirements. The initial term of the Fluidigm Agreement is five years. Both parties have the ability to extend the term for an additional five years. Under the expanded Supply Agreement, the term was extended until March 17, 2018, and the Company has the right to extend the term of the Supply Agreement for up to two additional three-year terms. The Company paid $44,721 and $93,224 related to these agreements in the three months ended March 31, 2017 and 2016, respectively. Under the Supply Agreement with Fluidigm, the Company had inventory purchases of $44,721 and $67,775 in the three months ended March 31, 2017 and 2016, respectively. In addition, the Company has several capital lease arrangements for laboratory equipment manufactured by Fluidigm. The Company paid $30,254 and $45,106 related to the leased equipment in the three months ended March 31, 2017 and 2016, respectively. In October 2016, the Company entered into an agreement with Merck Sharp & Dohme Corp., a wholly-owned subsidiary of Merck Co. & Inc. (“Merck”), an affiliate of Merck GHI, a principal stockholder of the Company and a related party to the Company. Under the agreement, Merck will provide access to its archive of over 200,000 bacterial pathogens. OpGen will initially perform molecular analyses on up to 10,000 pathogens to identify markers of resistance to support rapid decision making using the Acuitas Lighthouse, and to speed development of OpGen’s rapid diagnostic products. Merck will gain access to the high-resolution genotype data for the isolates as well as access to OpGen’s Acuitas Lighthouse informatics to support internal research and development programs. The Company is required to expend up to $175,000 for the procurement of materials related to the activities contemplated by the agreement. Contract life-to-date, the Company has incurred $91,403 of procurement costs which have been recognized as research and development expense, including $59,133 in the three months ended March 31, 2017.

Summary of significant accounting policies (Policies)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Basis of presentation and consolidation

Foreign currency

Use of estimates

Fair value of financial instruments

All financial instruments classified as current assets and liabilities are carried at cost, which approximates fair value, because of the short-term maturities of those instruments.

Cash and cash equivalents

Accounts receivable

Inventory

Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:

	March 31, 2017		December 31, 2016
Raw materials and supplies	$	410,945	$	479,479
Work-in process		68,031		27,422
Finished goods		163,985		185,467
Total	$	642,961	$	692,368

Property and equipment

Intangible assets and goodwill

Intangible assets and goodwill as of March 31, 2017 consist of finite-lived intangible assets and goodwill.

Finite-lived intangible assets

Finite-lived intangible assets include trademarks, developed technology and customer relationships and consisted of the following as of March 31, 2017 and December 31, 2016:

			March 31, 2017					December 31, 2016
	Cost		Accumulated Amortization			Net Balance		Accumulated Amortization			Net Balance
Trademarks and tradenames	$	461,000	$	(79,101	)	$	381,899	$	(67,575	)	$	393,425
Developed technology		458,000		(112,254	)		345,746		(95,898	)		362,102
Customer relationships		1,094,000		(267,601	)		826,399		(228,529	)		865,471
	$	2,013,000	$	(458,956	)	$	1,554,044	$	(392,002	)	$	1,620,998

Goodwill

Revenue recognition

Revenue from sales of QuickFISH, PNA FISH and XpressFISH diagnostic test products

Revenue is recognized upon shipment to the customer.

Revenue from providing laboratory services

The Company recognizes revenue associated with laboratory services contracts when the service has been performed and reports are made available to the customer.

Revenue from funded software development arrangements

Revenue from license arrangements

The Company recognizes revenue from licenses of its technologies over the applicable license term.

Revenue from sales of the reagents and supplies used for Argus consumable kits

Revenue is recognized for sales of the reagents and supplies used for Argus consumable kits upon shipment to the customer.

Share-based compensation

Income taxes

Loss per share

Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period.

Recent accounting pronouncements

Summary of significant accounting policies (Tables)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Schedule of Inventories

Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:

	March 31, 2017		December 31, 2016
Raw materials and supplies	$	410,945	$	479,479
Work-in process		68,031		27,422
Finished goods		163,985		185,467
Total	$	642,961	$	692,368

Schedule of Finite-Lived Intangible Assets

Finite-lived intangible assets include trademarks, developed technology and customer relationships and consisted of the following as of March 31, 2017 and December 31, 2016

			March 31, 2017					December 31, 2016
	Cost		Accumulated Amortization			Net Balance		Accumulated Amortization			Net Balance
Trademarks and tradenames	$	461,000	$	(79,101	)	$	381,899	$	(67,575	)	$	393,425
Developed technology		458,000		(112,254	)		345,746		(95,898	)		362,102
Customer relationships		1,094,000		(267,601	)		826,399		(228,529	)		865,471
	$	2,013,000	$	(458,956	)	$	1,554,044	$	(392,002	)	$	1,620,998

Stockholders' equity (Tables)

3 Months Ended

Mar. 31, 2017

Stockholders Equity Note [Abstract]

Schedule of Company Recognized Stock Compensation Expense

For the three months ended March 31, 2017 and 2016, the Company recognized stock compensation expense as follows:

	Three Months Ended March 31,
	2017		2016
Cost of services	$	1,823	$	4,312
Research and development		57,778		62,218
General and administrative		152,476		172,103
Sales and marketing		33,328		22,864
	$	245,405	$	261,497

Schedule of Warrants to Purchase Shares of Common Stock

Stock purchase warrants

At March 31, 2017 and December 31, 2016, the following warrants to purchase shares of common stock were outstanding:

				Outstanding at
Issuance	Exercise Price		Expiration	March 31, 2017		December 31, 2016
August 2007	$	7.91	August 2017		8,921		8,921
March 2008	$	790.54	March 2018		46		46
November 2009	$	7.91	November 2019		6,674		6,674
January 2010	$	7.91	January 2020		6,674		6,674
March 2010	$	7.91	March 2020		1,277		1,277
November 2011	$	7.91	November 2021		5,213		5,213
December 2011	$	7.91	December 2021		664		664
March 2012	$	109.90	March 2019		4,125		4,125
February 2015	$	6.60	February 2025		225,011		225,011
May 2015	$	6.60	May 2020		3,457,750		3,457,750
May 2016	$	1.31	May 2021		4,739,348		4,739,348
June 2016	$	1.31	May 2021		2,050,821		2,050,821
					10,506,524		10,506,524

Organization - Additional Information (Details)	3 Months Ended
Organization - Additional Information (Details)	Mar. 31, 2017 Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of operating business segment	1

Liquidity and Management's Plans - Additional Information (Details) - USD ($)		1 Months Ended	2 Months Ended	3 Months Ended
	Mar. 31, 2017	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2017	Mar. 31, 2016
Conversion Of Stock [Line Items]
Net proceeds from sale of common stock				$ 2,122,861	$ 0
Proceeds from issuance of private placement net			$ 9,500,000
Common Stock [Member] \| Promissory Note [Member] \| Merck GHI [Member]
Conversion Of Stock [Line Items]
Debt instrument, carrying amount	$ 1,000,000			$ 1,000,000
Debt instrument, maturity period				2017-07
Debt instrument, description				If the Company is unable to repay the note, negotiate its conversion or extend its term, the assets of the Company may be seized, as the note is secured by a lien on all the Company’s assets.
Private Placement [Member]
Conversion Of Stock [Line Items]
Proceeds from issuance of private placement net			$ 9,500,000
Class of warrant or right, number of securities called by warrants or rights			6,790,169
Class of warrant or right, exercise price of warrants or rights			$ 1.14
Sale of stock, description of transaction				(i) one share of common stock and a detachable stock purchase warrant to purchase an additional 0.75 shares of common stock, or (ii) one share of non-voting convertible preferred stock and a detachable stock purchase warrant to purchase an additional 0.75 shares of common stock, at a price of $1.14 per unit.
Private Placement [Member] \| Common Stock [Member]
Conversion Of Stock [Line Items]
Stock issued during period, shares, new issues			6,744,127
Private Placement [Member] \| Non-voting Convertible Preferred Stock [Member]
Conversion Of Stock [Line Items]
Stock issued during period, shares, new issues			2,309,428
Cowen and Company, LLC [Member] \| Sales Agreement [Member] \| At the Market Offering [Member]
Conversion Of Stock [Line Items]
Stock issued during period, value, new issues		$ 11,500,000
Maximum commission percentage on gross proceeds		3.00%
Net proceeds from sale of common stock	6,500,000			$ 2,100,000
Gross proceeds from sale of common stock	6,900,000			$ 2,200,000
Remaining availability under at the market offering	$ 4,600,000	$ 4,600,000
Cowen and Company, LLC [Member] \| Sales Agreement [Member] \| At the Market Offering [Member] \| Common Stock [Member]
Conversion Of Stock [Line Items]
Stock issued during period, shares, new issues	5,700,000			2,100,000
Cowen and Company, LLC [Member] \| Sales Agreement [Member] \| Maximum [Member] \| At the Market Offering [Member]
Conversion Of Stock [Line Items]
Aggregate gross proceeds from issuance of common stock		$ 25,000,000

Summary of Significant Accounting Policies - Additional Information (Details) shares in Millions	3 Months Ended
	Mar. 31, 2017 USD ($) Segment Customer shares	Mar. 31, 2016 USD ($) Customer shares	Dec. 31, 2016 USD ($)
Significant Accounting Policies [Line Items]
Number of operating business segment \| Segment	1
FDIC limit of insurable cash	$ 250,000
Letters of credit outstanding, amount	243,380		$ 243,380
Allowance for doubtful accounts receivable	$ 31,118		26,716
Number of individual customers accounting for more than 10% of revenue \| Customer	0	0
Number of individual customers accounting for more than 10% of accounts receivable \| Customer	0
Inventory valuation reserves	$ 134,679		704,516
Amortization of intangible assets	66,954	$ 66,954
Finite-lived intangible assets, amortization expense, next twelve months	268,000
Finite-lived intangible assets, amortization expense, 2019	268,000
Finite-lived intangible assets, amortization expense, 2020	268,000
Finite-lived intangible assets, amortization expense, 2021	268,000
Finite-lived intangible assets, amortization expense, 2022	268,000
Impairment of finite-lived intangible assets	0	$ 0
Goodwill	$ 600,814		600,814
Operating loss carryforwards			$ 151,000,000
Antidilutive securities excluded from computation of earnings per share, amount \| shares	14.0	5.9
Trademarks and Tradenames [Member]
Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life	10 years
Developed Technology [Member]
Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life	7 years
Customer Relationships [Member]
Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life	7 years
Minimum [Member]
Significant Accounting Policies [Line Items]
Accounts receivable period due	30 days
Maximum [Member]
Significant Accounting Policies [Line Items]
Accounts receivable period due	60 days

Summary of Significant Accounting Policies - Schedule of Inventories (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Inventories
Raw materials and supplies	$ 410,945	$ 479,479
Work-in process	68,031	27,422
Finished goods	163,985	185,467
Total	$ 642,961	$ 692,368

Summary of Significant Accounting Policies - Schedule of Finite-Lived Intangible Assets (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Cost	$ 2,013,000	$ 2,013,000
Accumulated Amortization	(458,956)	(392,002)
Net Balance	1,554,044	1,620,998
Trademarks and Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	461,000	461,000
Accumulated Amortization	(79,101)	(67,575)
Net Balance	381,899	393,425
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	458,000	458,000
Accumulated Amortization	(112,254)	(95,898)
Net Balance	345,746	362,102
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	1,094,000	1,094,000
Accumulated Amortization	(267,601)	(228,529)
Net Balance	$ 826,399	$ 865,471

2015 Merck GHI Financing - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended
	Jul. 31, 2015	Mar. 31, 2017	Mar. 31, 2016
Common Stock and Note Purchase Agreement [Line Items]
Proceeds from issuance of common stock, net of issuance costs		$ 2,122,861	$ 0
Merck GHI Financing Agreement [Member]
Common Stock and Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues	1,136,364
Shares issued, price per share	$ 4.40
Proceeds from issuance of common stock, net of issuance costs	$ 5,000,000
Debt instrument, interest rate, stated percentage	8.00%
Debt instrument, face amount	$ 1,000,000
Fees related to common stock and debt transaction	50,000
Deferred debt issuance costs	8,000
Adjustments to additional paid in capital, stock issued, issuance costs	$ 42,000

Fair value measurements (Details Textual) - USD ($)	3 Months Ended
Fair value measurements (Details Textual) - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets transferred between fair value measurement levels	$ 0
Fair Value on Recurring Basis [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Financial assets measured at fair value	0
Financial liabilities measured at fair value	0
Non-financial assets measured at fair value	0
Non-financial liabilities measured at fair value	0
Fair Value on Non-Recurring Basis [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Financial assets measured at fair value	0
Financial liabilities measured at fair value	0
Impairment of non-financial assets and liabilities at fair value	$ 0	$ 0

Debt (Details Textual) - USD ($)	3 Months Ended
Debt (Details Textual) - USD ($)	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Debt Instrument [Line Items]
Interest expense, debt	$ 29,844	$ 41,734
Merck GHI Financing Agreement [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,000,000		$ 1,000,000

Stockholders' equity (Details Textual) - USD ($)				1 Months Ended			2 Months Ended	3 Months Ended
Stockholders' equity (Details Textual) - USD ($)	Mar. 31, 2017	Apr. 28, 2016	Jan. 01, 2016	Sep. 30, 2016	Jun. 30, 2016	May 31, 2016	Jun. 30, 2016	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized	200,000,000							200,000,000			200,000,000
Common stock, shares issued	27,377,490							27,377,490			25,304,270
Common stock, shares outstanding	27,377,490							27,377,490			25,304,270
Preferred stock, shares authorized	10,000,000							10,000,000			10,000,000
Preferred stock, shares issued	0							0			0
Preferred stock, shares outstanding	0							0			0
Proceeds from issuance of common stock, net of issuance costs								$ 2,122,861	$ 0
Proceeds from issuance of private placement net							$ 9,500,000
Convertible preferred stock, beneficial conversion feature recognized as deemed dividend								$ 332,550
Share-based compensation arrangement by share-based payment award, options, grants in period, gross								723,600
Share-based compensation, tax benefit from compensation expense								$ 0
Share-based compensation arrangements by share-based payment award, options, grants in Period, weighted average exercise price								$ 1.03
Share-based compensation arrangement by share-based payment award, options, forfeitures in period								4,863
Share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price								$ 1.82
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value								$ 0.54
Share-based compensation arrangement by share-based payment award, options, outstanding, number	3,514,071							3,514,071
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period										75,000
Share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, weighted average grant date fair value										$ 1.70
Share-based compensation arrangement by share-based payment award, equity instruments other than options, non-vested, outstanding	18,750							18,750
Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period								0
Share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period								0
Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, options, grants in period, gross		766,500
Percentage of total outstanding shares of common stock		6.00%
Share based compensation arrangements by share based payment award options grants in period exercise price		$ 1.35
Share based compensation arrangements by share based payment award contractual term		10 years
Chief Executive Officer [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage		25.00%
Chief Executive Officer [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage		6.25%
2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares authorized	1,355,000							1,355,000
Share-based compensation arrangement by share-based payment award, description								the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Company’s Board of Directors.
Share-based compensation arrangement by share-based payment award, number of shares available for grant	1,145,402							1,145,402
Share-based compensation arrangement by share-based payment award, common stock percentage								4.00%
Share-based compensation arrangement by share-based payment award, number of additional shares authorized			1,012,171
May 2016 Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, exercise price of warrants or rights						$ 1.3125
Warrant expiration period						5 years
Expiration date of warrants issued								May 18, 2021
June 2016 Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, exercise price of warrants or rights					$ 1.3125		$ 1.3125
Warrant expiration period					5 years
Expiration date of warrants issued								May 18, 2021
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Conversion of stock, shares issued								2,309,428
Non-voting Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Conversion of stock, shares converted								2,309,428
Private Placement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by each warrant or right					0.75		0.75
Class of warrant or right, number of securities called by warrants or rights					6,790,169		6,790,169
Class of warrant or right, exercise price of warrants or rights					$ 1.14		$ 1.14
Sale of stock, description of transaction								(i) one share of common stock and a detachable stock purchase warrant to purchase an additional 0.75 shares of common stock, or (ii) one share of non-voting convertible preferred stock and a detachable stock purchase warrant to purchase an additional 0.75 shares of common stock, at a price of $1.14 per unit.
Proceeds from issuance of private placement net							$ 9,500,000
Private Placement [Member] \| Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues							6,744,127
Private Placement [Member] \| Non-voting Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues							2,309,428
Cowen and Company, LLC [Member] \| At the Market Offering [Member] \| Sales Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues				$ 11,500,000
Maximum commission percentage on gross proceeds				3.00%
Remaining availability under at the market offering	$ 4,600,000			$ 4,600,000
Proceeds from issuance of common stock, net of issuance costs	6,500,000							$ 2,100,000
Gross proceeds from sale of common stock	$ 6,900,000							$ 2,200,000
Cowen and Company, LLC [Member] \| At the Market Offering [Member] \| Sales Agreement [Member] \| Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues	5,700,000							2,100,000
Maximum [Member] \| Cowen and Company, LLC [Member] \| At the Market Offering [Member] \| Sales Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate gross proceeds from issuance of common stock				$ 25,000,000

Stockholders' equity - Company Recognized Stock Compensation Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	$ 245,405	$ 261,497
Cost of Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	1,823	4,312
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	57,778	62,218
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	152,476	172,103
Sales and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	$ 33,328	$ 22,864

Stockholders' equity - Warrants to Purchase Shares of Common Stock (Details) - $ / shares	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of Common Stock Subject to Warrants	10,506,524	10,506,524
August 2007 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91
Expiration	2017-08
Shares of Common Stock Subject to Warrants	8,921	8,921
March 2008 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 790.54
Expiration	2018-03
Shares of Common Stock Subject to Warrants	46	46
November 2009 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91
Expiration	2019-11
Shares of Common Stock Subject to Warrants	6,674	6,674
January 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91
Expiration	2020-01
Shares of Common Stock Subject to Warrants	6,674	6,674
March 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91
Expiration	2020-03
Shares of Common Stock Subject to Warrants	1,277	1,277
November 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91
Expiration	2021-11
Shares of Common Stock Subject to Warrants	5,213	5,213
December 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91
Expiration	2021-12
Shares of Common Stock Subject to Warrants	664	664
March 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 109.90
Expiration	2019-03
Shares of Common Stock Subject to Warrants	4,125	4,125
February 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 6.60
Expiration	2025-02
Shares of Common Stock Subject to Warrants	225,011	225,011
May 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 6.60
Expiration	2020-05
Shares of Common Stock Subject to Warrants	3,457,750	3,457,750
May 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.31
Expiration	2021-05
Shares of Common Stock Subject to Warrants	4,739,348	4,739,348
June 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.31
Expiration	2021-05
Shares of Common Stock Subject to Warrants	2,050,821	2,050,821

Commitments (Details Textual) - USD ($)	3 Months Ended
Commitments (Details Textual) - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Other Commitments [Line Items]
Operating lease description	The Company leases a facility in Woburn, Massachusetts under an operating lease that expires January 30, 2022. The Company also leases a facility in Gaithersburg, Maryland under an operating lease that expires January 31, 2021, with one additional five-year renewal at the Company’s election. Additionally, the Company leases office space in Denmark; this lease is currently on a month-to-month basis.
Operating leases, rent expense, net, total	$ 232,836	$ 254,044
Capital leases description	The Company leases computer equipment, office furniture, and equipment under various capital leases. The leases expire at various dates through 2021. The leases require monthly principal and interest payments.
Capital leases expiration date description	The leases expire at various dates through 2021.
Facility in Woburn, Massachusetts [Member] \| AdvanDx [Member]
Other Commitments [Line Items]
Operating leases expiration date	Jan. 30, 2022
Gaithersburg, Maryland Office Lease [Member]
Other Commitments [Line Items]
Operating leases expiration date	Jan. 31, 2021
Operating leases additional term	5 years

License agreements, research collaborations and development agreements (Details Textual)	3 Months Ended
	Mar. 31, 2017 USD ($) Agreement	Mar. 31, 2016 USD ($)
License Agreements Research Collaborations And Development Agreements [Line Items]
Number of license agreements \| Agreement	5
Royalty expense	$ 69,245	$ 69,854
Annual future minimum royalty payments due	250,000
Collaborations revenue	21,164	$ 0
License Agreement with Hitachi [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Collaborations revenue	$ 6,164
FISH Product Line [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Number of license agreements \| Agreement	2
Argus and MapIt Product Lines [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Number of license agreements \| Agreement	3

Related party transactions (Details Textual) - USD ($)	3 Months Ended		5 Months Ended
Related party transactions (Details Textual) - USD ($)	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Oct. 31, 2016
Merck Sharp & Dohme Corp [Member]
Related Party Transaction [Line Items]
Research and development agreement description	Under the agreement, Merck will provide access to its archive of over 200,000 bacterial pathogens. OpGen will initially perform molecular analyses on up to 10,000 pathogens to identify markers of resistance to support rapid decision making using the Acuitas Lighthouse, and to speed development of OpGen’s rapid diagnostic products. Merck will gain access to the high-resolution genotype data for the isolates as well as access to OpGen’s Acuitas Lighthouse informatics to support internal research and development programs.
Maximum required amount to expend for procurement of materials				$ 175,000
Merck Sharp & Dohme Corp [Member] \| Research and Development Expense [Member]
Related Party Transaction [Line Items]
Procurement costs recognized	$ 59,133		$ 91,403
Fluidigm Corporation Supply Agreement [Member]
Related Party Transaction [Line Items]
Contractual agreement period	5 years
Additional contractual agreement period	5 years
Contractual agreement maturity date	Mar. 17, 2018
Contractual agreement description	The initial term of the Fluidigm Agreement is five years. Both parties have the ability to extend the term for an additional five years. Under the expanded Supply Agreement, the term was extended until March 17, 2018, and the Company has the right to extend the term of the Supply Agreement for up to two additional three-year terms.
Related party transaction, expenses from transactions with related party	$ 44,721	$ 93,224
Related party transaction, purchases from related party	44,721	67,775
Payments to acquire equipment on lease	$ 30,254	$ 45,106